Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors

Zuo, Ke; Qi, Yana; Yuan, Cai; Jiang, Longguang; Xu, Peng; Hu, Jianping; Huang, Mingdong; Li, Jinyu

doi:10.1007/s10555-019-09802-8

Cited by 16 publications

(9 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proliferation is one of the vital characteristics of tumors which contributes to cancer development and progression [9]. In light of the important role in tumors, targeting proliferation is a promising therapeutic strategy.…”

Section: Discussionmentioning

confidence: 99%

UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway

Liang¹,

Zhu²

2021

J. Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway

Liang¹,

Zhu²

2021

J. Cancer

View full text Add to dashboard Cite

“…Next, the potential biological role of PTK7 in OSCC cells was investigated using sh-PTK7. Cancer cell proliferation determines cancer progression, and metastasis, characterized by cancer cell migration and invasion, represents a significant challenge in the clinical treatment of various types of cancer (31). Therefore, the current study sought to determine the effect of PTK7 on OSCC cell proliferation, migration and invasion.…”

Section: Discussionmentioning

confidence: 99%

Protein tyrosine kinase 7‑knockdown inhibits oral squamous cell carcinoma cell viability, proliferation, migration and invasion via downregulating dishevelled segment polarity protein 3 expression

Jin

Huang

Ma³

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Protein tyrosine kinase 7 (PTK7) expression has been reported to be dysregulated and to regulate various cellular activities in numerous types of cancer. However, to the best of our knowledge, the status and role of PTK7 in oral squamous cell carcinoma (OSCC) remains largely unknown. The present study aimed to investigate the involvement of PTK7 in OSCC progression and to determine the potential underlying mechanisms of action. The expression levels of PTK7 and dishevelled segment polarity protein 3 (DVL3) in OSCC cell lines were analyzed using reverse transcription-quantitative PCR and western blotting. A co-immunoprecipitation assay was used to verify the binding association between PTK7 and DVL3. In addition, OSCC cells were transfected with a short hairpin RNA targeting PTK7 or pcDNA-DVL3 overexpression vectors. The effect of PTK7 on OSCC cell viability, proliferation, migration and invasion, and the underlying mechanisms, were investigated using Cell Counting Kit-8, colony formation, wound healing and Transwell assays, respectively. Western blotting was used to analyze the expression levels of proliferation-and migration-associated proteins. The results revealed that the expression levels of both PTK7 and DVL3 were significantly upregulated in OSCC cell lines. In addition, a binding association was identified between PTK7 and DVL3 in SCC-9 cells. The knockdown of PTK7 expression inhibited OSCC cell viability, proliferation, invasion and migration, while the overexpression of DVL3 reversed the inhibitory effects of PTK7-knockdown on OSCC cells. In conclusion, the results of the present study suggested that PTK7 may be a key regulator of OSCC proliferation, migration and invasion, and PTK7-knockdown may inhibit OSCC cell viability, proliferation, invasion and migration by downregulating DVL3 expression. Therefore, PTK7 and DVL3 may represent potential biomarkers for diagnosis and treatment, as well as promising drug targets for OSCC.

show abstract

“…Multiple in vitro studies suggest a role for PAR2 in cancer development, including induction of cell migration, proliferation, metastasis and angiogenesis [30,36,37]. These reports of enhanced expression of PAR2 in cancer pathogenesis have led to it being promoted as a drug target worthy of investigation [26,27].…”

Section: Discussionmentioning

confidence: 99%

Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines

et al. 2021

View full text Add to dashboard Cite

Expression of the protease sensing receptor, protease activated receptor-2 (PAR2), is elevated in a variety of cancers and has been promoted as a potential therapeutic target. With the development of potent antagonists for this receptor, we hypothesised that they could be used to treat renal cell carcinoma (RCC). The expression of PAR2 was, therefore, examined in human RCC tissues and selected RCC cell lines. Histologically confirmed cases of RCC, together with paired non-involved kidney tissue, were used to produce a tissue microarray (TMA) and to extract total tissue RNA. Immunohistochemistry and qPCR were then used to assess PAR2 expression. In culture, RCC cell lines versus primary human kidney tubular epithelial cells (HTEC) were used to assess PAR2 expression by qPCR, immunocytochemistry and an intracellular calcium mobilization assay. The TMA revealed an 85% decrease in PAR2 expression in tumour tissue compared with normal kidney tissue. Likewise, qPCR showed a striking reduction in PAR2 mRNA in RCC compared with normal kidney. All RCC cell lines showed lower levels of PAR2 expression than HTEC. In conclusion, we found that PAR2 was reduced in RCC compared with normal kidney and is unlikely to be a target of interest in the treatment of this type of cancer.

show abstract

Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors

Cited by 16 publications

References 93 publications

UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway

UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway

Protein tyrosine kinase 7‑knockdown inhibits oral squamous cell carcinoma cell viability, proliferation, migration and invasion via downregulating dishevelled segment polarity protein 3 expression

Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines

Contact Info

Product

Resources

About